TIZIANA LIFE SCIENCES LTD

NASDAQ: TLSA (Tiziana Life Sciences Ltd)

Last update: yesterday, 8:09AM

1.74

-0.03 (-1.69%)

Previous Close 1.77
Open 1.74
Volume 156,887
Avg. Volume (3M) 332,187
Market Cap 206,753,776
Price / Book 22.99
52 Weeks Range
0.630 (-63%) — 2.60 (49%)
Earnings Date 23 Jun 2025 - 8 Jul 2025
Diluted EPS (TTM) -0.110
Total Debt/Equity (MRQ) 2.69%
Current Ratio (MRQ) 1.02
Operating Cash Flow (TTM) -1.53 M
Levered Free Cash Flow (TTM) -8.99 M
Return on Assets (TTM) -84.13%
Return on Equity (TTM) -250.49%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Bullish Mixed
Biotechnology (Global) Bullish Mixed
Stock Tiziana Life Sciences Ltd Mixed Mixed

AIStockmoo Score

-0.9
Analyst Consensus 2.0
Insider Activity NA
Price Volatility -1.0
Technical Moving Averages -2.5
Technical Oscillators -2.0
Average -0.88

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
TLSA 207 M - - 22.99
MESO 2 B - - 3.70
TSHA 1 B - - 5.08
SANA 1 B - - 6.10
NTLA 1 B - - 1.32
ORIC 1 B - - 2.83

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.

Sector Healthcare
Industry Biotechnology
Investment Style Small Value
% Held by Insiders 43.06%
% Held by Institutions 2.73%

Ownership

Name Date Shares Held
Dauntless Investment Group, Llc 30 Sep 2025 2,735,933
Ewa, Llc 30 Sep 2025 46,050
Date Type Details
02 Dec 2025 Announcement Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company
02 Dec 2025 Announcement Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company
25 Nov 2025 Announcement Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program
25 Nov 2025 Announcement Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program
13 Nov 2025 Announcement Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference
13 Nov 2025 Announcement Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference
29 Oct 2025 Announcement Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy
29 Oct 2025 Announcement Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy
30 Sep 2025 Announcement Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia
30 Sep 2025 Announcement Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia
25 Sep 2025 Announcement Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody
25 Sep 2025 Announcement Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody
24 Sep 2025 Announcement Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress
24 Sep 2025 Announcement Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress
15 Sep 2025 Announcement Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury
15 Sep 2025 Announcement Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury
09 Sep 2025 Announcement Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
09 Sep 2025 Announcement Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
09 Sep 2025 Announcement Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
09 Sep 2025 Announcement Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria